THE European Medicines
Agency’s Committee for Medicinal
Products for Human Use (CHMP)
has recommended ten new
medicines for approval.
The additions include the first two
monoclonal antibody biosimilars,
Remsima and Inflectra with the
same indication as Remicade,
as well as 3 cancer therapies:
Provenge, Tafinlar and Stivarga.
Also approved are Procysbi for
the management of cystinosis and
Lemtrada for MS.
The remaining recommendations
were for Cholib for reduction of CV
risk, Nexium Control for reflux and
Evarrest for haemostasis.The above article was sent to subscribers in Pharmacy Daily's issue from 01 Jul 13 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 01 Jul 13
PEAK pharmacy bodies are calling on the Australian Government to extend the new Commonwealth Prac Payment to pharmacy students, citing the challenges of “placement poverty” in unpaid practical placements.
AFT Pharmaceuticals is set to develop a topical treatment for keloid and hypertrophic scarring in partnership with NZ’s Massey Ventures, the commercialisation arm of Massey University, and the Gillies McIndoe Research Institute.
THE Pharmaceutical Society of Australia (PSA) awarded Brooke Shelly the prestigious 2024 PSA MIMS Credentialed Pharmacist of the Year award last Fri at the Credentialed Pharmacist Conference (CPC24) (PD breaking news).
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.